Immuron Ltd — Capital/Financing Update 2016

Jun 13, 2016

==> picture [201 x 53] intentionally omitted <==

Immuron Extends Closing Date of Rights Issue

Melbourne, Australia, 14 June 2016: Australian microbiome biopharmaceutical company Immuron Limited (ASX: IMC) advises that it will extend the Closing Date of its $6M Rights Issue from 20[th] June 2016 to Thursday 30[th] June 2016.

The Company believes that the extension of the Closing Date will provide shareholders with the benefit of having additional time to consider new hopefully soon to be released additional information surrounding the Company’s products prior to finalising their investment decision in relation to participation in the Rights Issue. This new information should hopefully be finalised and released to the market in the coming days,

The Rights Issue provides eligible shareholders with the opportunity to participate in a three (3) for ten (10) nonrenounceable entitlement offer of new IMC shares (New Shares) at an issue price of $0.25 per New Share to raise up to $6M (before costs) (Rights Issue or Entitlement Offer). For each New Share allotted, eligible participants will receive one (1) free-attaching option exercisable at $0.55 per option expiring three years from the date of issue (New Option). The issuance of New Options will be subject to approval at a shareholder meeting expected to be held in July 2016. Assuming the criteria for official quotation is met, the Company will seek quotation for the New Options on the ASX.

The Company is pleased to advise that it has received $3M in Firm Commitments for securities under the Offer. Following successful completion of the Rights Issue, the company expects to be funded through to what it sees to be major valuation inflections (NASH interim analysis and European registration trial initiation, expected in Q4, 2016). The interim results analysis will take place with 30 patients, to date 25 patients have completed treatment in the trial.

Updated Timetable

Indicative Timetable - Event	Original Date	New Date
Closing Date	Mon, 20 June 2016	Thurs, 30 June 2016
Notification to ASX of under-subscriptions	Thurs, 23 June 2016	Tues, 5 July 2016
Allotment of New Shares	Mon, 27 June 2016	Thurs, 7 July 2016
Commencement of normal trading	Tues, 28 June 2016	Fri, 8 July 2016

Important information

Nothing contained in this announcement constitutes investment, legal, tax or other advice. You should make your own assessment and take independent professional advice in relation to the information and any action taken on the basis of the information.

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

==> picture [76 x 23] intentionally omitted <==

About Immuron

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. This mix of clinical and on-market assets offer investors a unique investment opportunity in the biotech sector.

For more information visit: http://www.immuron.com/

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Page 2 of 2